What is the recommended management for a multifocal high‑grade bladder tumor?

Management of Multifocal High-Grade Bladder Tumor

For multifocal high-grade bladder tumors, perform a complete transurethral resection (TURBT) followed by a mandatory repeat TURBT within 2-6 weeks, then initiate intravesical BCG therapy with maintenance for 1-3 years; however, strongly consider early radical cystectomy with extended lymphadenectomy, particularly if there is concomitant carcinoma in situ (CIS), prostatic involvement, or BCG failure. 1

Initial Surgical Management

Primary TURBT

• Perform complete transurethral resection with examination under anesthesia 1
• Critical requirement: muscle must be present in the pathology specimen for accurate staging 1
• If no muscle is present in the specimen for high-grade disease, this is a major red flag requiring immediate action 1
• Consider selected mapping biopsies if sessile or suspicious for high grade 1
• Consider TUR biopsy of the prostate, especially if tumor involves trigone or bladder neck 1

Mandatory Repeat TURBT

A second TURBT is not optional—it should be performed within 2-6 weeks for all high-grade tumors 1, 2. This is essential because:

• It reduces the rate of residual tumor left behind
• It improves staging accuracy (critical for multifocal disease where understaging is common)
• It provides better prognostic information for treatment decisions

Risk Stratification for Multifocal High-Grade Disease

Your patient falls into the high-risk or very high-risk category based on multifocality and high grade 1, 2. The presence of additional factors significantly worsens prognosis:

Very high-risk features that should prompt immediate cystectomy consideration:

• Multiple high-grade T1 tumors 1
• Concomitant CIS (carcinoma in situ) 1, 3, 4
• Prostatic urethral involvement 3, 4
• Lymphovascular invasion 5
• Residual T1 tumor after repeat resection 5
• Tumor at difficult-to-resect sites 5, 3

Definitive Treatment Algorithm

Option 1: Radical Cystectomy (Preferred for Very High-Risk)

Immediate radical cystectomy with extended bilateral pelvic lymphadenectomy should be strongly considered for multifocal high-grade disease, especially in younger patients with additional poor prognostic factors 1, 6.

Why cystectomy is preferred in this context:

• Multifocal high-grade tumors have substantial risk of understaging (approximately 50% may have occult muscle invasion) 7
• Risk of progression to muscle-invasive disease is high if managed conservatively 5, 3
• Postponing cystectomy until progression occurs may negatively impact survival 5
• Excellent survival outcomes when performed early 7

Lymphadenectomy requirements:

• Must include at minimum: common iliac, internal iliac, external iliac, and obturator nodes 1
• Extended lymphadenectomy has been shown to be beneficial and may be curative even with micrometastases 6

Option 2: Bladder-Sparing Approach with BCG

If the patient refuses cystectomy or has significant comorbidities, proceed with intravesical BCG therapy 1:

BCG Protocol:

• Full-dose BCG (not reduced dose) for 1-3 years with maintenance is mandatory 1, 5
• Induction: 6 weekly instillations
• Maintenance: Critical for high-risk disease—studies show 1/3 dose or one-year full dose are suboptimal 5
• Category 1 recommendation for high-grade disease 1

Common pitfall to avoid: Do not use reduced-dose BCG for high-risk multifocal disease—the CUETO and EORTC trials showed this is inferior 5

Surveillance and Response Assessment

Initial Evaluation (3 months after BCG induction):

• Cystoscopy with cytology 1, 6
• Biopsy of any suspicious areas
• This 3-month evaluation is critical for determining BCG response

If Complete Response at 3 Months:

• Continue BCG maintenance
• Cystoscopy and cytology every 3 months for 2 years 6
• Then every 6 months until 5 years
• Then annually 6
• Upper tract imaging every 1-2 years 1

If BCG Failure or Recurrence:

BCG-unresponsive disease is defined as:

• Persistent or recurrent high-grade disease at 3 months despite adequate BCG
• Recurrence of high-grade T1 disease during maintenance
• Progression to higher stage

Management of BCG failure:

1. Radical cystectomy is strongly recommended 8, 5—this is the standard of care
2. If patient refuses or is unfit for cystectomy, alternative options include:
   • Gemcitabine/docetaxel combination intravesical therapy 7, 9
   • Device-assisted chemotherapy (EMDA, Synergo with mitomycin C) 5
   • Clinical trial enrollment (immunotherapy trials) 7
   • Pembrolizumab or nadofaragene firadenovec for BCG-unresponsive disease 8, 10

Special Considerations for Multifocal Disease

Panurothelial disease risk: Patients with multifocal high-grade tumors and associated CIS are at very high risk for developing disease throughout the entire urothelium, including upper tracts and prostatic urethra 4. This population has:

• High rate of bilateral upper tract involvement (34-41%) 4
• Poor prognosis if concurrent bladder CIS and prostate involvement develop early 4
• May require extended excision considerations at time of cystectomy 4

When BCG is Unavailable

Given ongoing BCG shortages 8, 7, if BCG is not available for your multifocal high-grade patient:

Priority order:

1. Immediate radical cystectomy—this eliminates the BCG shortage problem and provides excellent survival for high-risk disease 7
2. Intravesical gemcitabine/docetaxel combination 7, 9
3. Mitomycin C (though inferior to BCG for high-risk disease) 1
4. Clinical trial enrollment 7

Critical warning: Approximately 50% of patients with multifocal high-grade Ta disease may be understaged, meaning conservative approaches risk missing occult muscle invasion 7. This makes the decision between cystectomy and bladder preservation particularly consequential.

Bottom Line Decision Framework

Choose immediate radical cystectomy if:

• Young patient (<70 years)
• Multiple high-grade T1 tumors
• Concomitant CIS present
• Prostatic involvement
• Recurrence as T1 high-grade at 3 months
• Patient preference for definitive treatment

Choose BCG bladder-sparing approach if:

• Older patient with comorbidities
• Patient strongly desires bladder preservation
• Solitary high-grade lesion (not your case—you have multifocal)
• No CIS or prostatic involvement
• Patient understands and accepts higher surveillance burden and risk

For your specific scenario of multifocal high-grade disease, the evidence strongly favors either immediate cystectomy or, if bladder preservation is attempted, full-dose BCG with maintenance for 1-3 years with very close surveillance and low threshold for salvage cystectomy at first sign of BCG failure 1, 5, 3.